darapladib

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

no benefit for patients with acute or chronic coronary artery disease^[1]

Dosage

160 mg PO QD

Adverse effects

diarrhea
odor-related concerns

Mechanism of action

inhibits phospholipase A2

Notes

experimental agent

More general terms

enzyme inhibitor

References

↑ ^1.0 ^1.1 O'Donoghue ML et al. Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 Randomized Clinical Trial. JAMA 2014 Aug 31 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25173516 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1900827

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9939609

Retrieved from "https://aaushi.info/w/index.php?title=A445389&oldid=914711"

↑ Back to top